Baird raised the firm’s price target on Elevance Health (ELV) to $331 from $317 and keeps a Neutral rating on the shares. The firm updated its model following Q1 results which suggests its fundamental story is firming up.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ELV:
- AI Models Turn More Positive on Elevance Health After Guidance Boost
- Elevance Health Earnings Call Highlights Growth, Key Risks
- Elevance Health reports Q1 adjusted EPS $12.58, consensus $10.81
- Elevance Health raises FY26 adjusted EPS view to ‘at least $26.75’
- Elevance Health backs FY26 operating cash flow view ‘at least $5.5B’